D-BOX Reports Record Full-Year Revenue and Profitability for Fiscal 2025
Royalty-driven Model delivers Strong Margin Expansion and Cash Generation; Leadership Transition positions Company for Next Phase of Growth
All dollar amounts are expressed in Canadian currency(1) Please refer to "non-IFRS and other financial performance measures" in this press release
Fiscal 2025 Highlights
Record total revenues of $42.8 million, up 8% vs. FY 2024
Record royalties of $11 million, up 27% vs. FY 2024
Adjusted EBITDA1 of $7.3 million, or 17% of total revenues, up 9 pts vs. FY 2024
Net profit of $3.9 million, up 254% year-over-year, or fully diluted EPS of $0.02
Cash flow from operating activities of $7.3 million
Liquidity of approximately $16 million as of March 31, 2025
Fourth Quarter Highlights
Total revenues of $8.6 million, down 15% vs. Q4 2024
Royalties of $2.2 million, up 5% year-over-year
Adjusted EBITDA margin1 of 18%, up 12 pts vs. Q4 2024
Net profit of $0.7 million
MONTREAL, June 10, 2025 (GLOBE NEWSWIRE) -- D-BOX Technologies Inc. ('D-BOX' or the "Company") (TSX: DBO) today reported financial results for its fourth quarter and full year ended March 31, 2025.
'In Q4 2025, D-BOX delivered robust performance with strong royalty growth, improved profitability, and a resilient core business,' said Brigitte Bourque, Chair of the Board. 'For the full fiscal year 2025, the Company achieved record revenues and net income, driven by the strength of our royalty-focused model and disciplined expense control.'
Q4 and Full-Year 2025 Operating Results
In Q4 2025, total revenues were $8.6 million, down 15% year-over-year, primarily reflecting the earlier-than-expected fulfillment of Theatrical system sales in Q3, partially offset by growth in Simulation training and Sim racing markets. The $3.4 million decline in Theatrical system sales was partially offset by strong growth in royalties and Sim racing. Royalties increased by 5 percent to $2.2 million, driven by an expanded global footprint reaching 1,012 screens, up 9% from the previous year, as well as successful Hollywood content with blockbusters in the fourth quarter including Captain America: Brave New World, Sonic the Hedgehog 3 and Mufasa: The Lion King. Simulation and training and Sim racing customer groups also grew 47% and 108% year-over-year, respectively, in the fourth quarter. Total revenues also benefited from favourable movements in currency exchange rates.
For the full year, D-BOX reported record total revenues of $42.8 million, up 8% compared to fiscal 2024. Excluding the impact of our exit from the direct-to-consumer (DTC) hardware market, FY 2025 revenue would have increased by just over 10% year-over-year. Royalties reached $11 million, accounting for an increased 26% share of the Company's revenue mix.
Adjusted EBITDA1 for the year totaled $7.3 million, representing an 18% Adjusted EBITDA margin1, reflecting prudent cost control. Net profit was $3.9 million, with operating cash flow of $7.3 million.
Given the inherent variability and seasonality of quarterly sales, we emphasize the importance of assessing the Company's performance on a trailing twelve-month basis.
(Amounts are in thousands of Canadian dollars)
Q4 2025
Q4 2024
Var.($)
Var. (%)
FY 2025
FY 2024
Var.($)
Var. (%)
Revenues from
System sales
Theatrical
992
4,443
(3,451)
(78%)
10,362
11,305
(943)
(8%)
Simulation and training
2,408
1,635
773
47%
8,606
8,825
(219)
(2%)
Sim racing
2,682
1,290
1,392
108%
10,020
7,112
2,908
41%
Other
286
685
(399)
(58%)
2,771
3,656
(885)
(24%)
Total system sales
6,368
8,053
(1,685)
(21%)
31,759
30,898
861
3%
Rights for use, rental and maintenance ("royalties")
2,241
2,126
115
5%
11,028
8,699
2,329
27%
Total Revenues
8,609
10,179
(1,570)
(15%)
42,787
39,597
3,190
8%
Leadership Transition
As announced on June 4, 2025, the Board appointed Naveen Prasad as Interim CEO, effective June 10, following the departure of Sébastien Mailhot. https://www.d-box.com/en/news/d-box-technologies-announces-ceo-change
'It has been an incredible journey over the past five years,' said Sébastien Mailhot. 'I am very proud of how we have grown revenues and significantly improved profitability while building a team that is now well-positioned for the future. I leave knowing that D-BOX has tremendous opportunities ahead. I wish Naveen and the broader team continued success.'
'We are confident that Naveen will be effective driving the next phase of strategic growth and value creation for all stakeholders,' added Ms. Bourque.
Balance Sheet and Liquidity
D-BOX closed fiscal 2025 in a position of financial strength, with $7.3 million in operating cash flow, low-cost total debt of $1.2 million, and available liquidity including the undrawn line of credit, of approximately $16 million.
SUPPLEMENTAL FINANCIAL DATA - UNAUDITED
(Amounts are in thousands of Canadian dollars)
Q4 2025
Q4 20242
Var. (%)
FY 2025
FY 20242
Var. (%)
Total Revenues
8,609
10,179
(15%)
42,787
39,597
8%
Gross profit
4,661
4,734
(2%)
22,327
18,660
20%
Operating expenses
3,875
4,052
(4%)
17,991
17,005
6%
Operating income
786
682
15%
4,336
1,655
162%
Adjusted EBITDA1
1,578
620
155%
7,311
3,056
139%
Financial expenses
61
97
(37%)
452
590
(23%)
Net profit
720
585
23%
3,858
1,058
265%
Basic and diluted EPS
0.003
0.003
n.m.
0.017
0.005
260%
Gross margin1
54%
47%
7 p.p.
52%
47%
5 p.p.
Operating expenses as % of total revenues1
45%
40%
5 p.p.
42%
43%
(1 p.p.)
Operating margin1
9%
7%
2 p.p.
10%
4%
6 p.p.
Adjusted EBITDA margin1
18%
6%
12 p.p.
17%
8%
9 p.p.
Cash flows provided by operating activities
7,324
3,125
134%
As at (in thousands of Canadian dollars)
Mar. 31, 2025
Mar. 31, 2024
Total debt1
1,221
2,468
Cash and cash equivalents
7,812
2,916
Net cash (net debt) 1
6,591
448
Adjusted EBITDA (LTM) 1
7,311
3,056
Total debt to adjusted EBITDA (LTM) 1
0.2x
0.8x
1) Please refer to "non-IFRS and other financial performance measures" in this press release2) Results for the fourth quarter and full year 2024 reflect a $0.5 million one-time gain on the sale of an investment. n.m.= not meaningful
This release should be read in conjunction with the Company's audited consolidated financial statements and the Management's Discussion and Analysis dated June 10, 2025. These documents are available at www.sedarplus.ca.
NON-IFRS AND OTHER FINANCIAL PERFORMANCE MEASURES
D-BOX uses the following non-IFRS financial performance measures in its MD&A and other communications. The non-IFRS measures do not have any standardized meaning prescribed by IFRS and are unlikely to be comparable to similarly titled measures reported by other companies. Investors are cautioned that the disclosure of these metrics is meant to add to, and not to replace, the discussion of financial results determined in accordance with IFRS. Management uses both IFRS and non-IFRS measures when planning, monitoring and evaluating the Company's performance. The non-IFRS performance measures are described as follows:
Adjusted EBITDA
EBITDA represents earnings before interest and financing, income taxes and depreciation and amortization. Adjustments to EBITDA are for items that are not necessarily reflective of the Company's underlying operating performance. As there is no generally accepted method of calculating EBITDA, this measure is not necessarily comparable to similarly titled measures reported by other issuers. Adjusted EBITDA provides useful and complementary information, which can be used, in particular, to assess profitability and cash flow from operations. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by total revenues. A reconciliation of net profit to Adjusted EBITDA margin is in the Company's Management's Discussion and Analysis dated June 10, 2025.
Total Debt, Net Debt and Total Debt to Adjusted EBITDA
Total debt is defined as the total bank indebtedness, long-term debt (including any current portion), and net debt is calculated as total debt net of cash and cash equivalents. The Company considers total debt and net debt to be important indicators for management and investors to assess the financial position and liquidity of the Company and measure its financial leverage. These measures do not have any standardized meanings prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Total debt to Adjusted EBITDA ratio is calculated as total net debt divided by the last four quarters Adjusted EBITDA. We believe that total debt to Adjusted EBITDA is a useful metric to assess the Company's ability to manage debt and liquidity.
Supplementary Financial Measures
Gross margin is defined as gross profit divided by total revenues.
Operating expenses as a percentage of sales are defined as operating expenses divided by total revenues.
Operating margin is defined as operating income divided by net sales.
ABOUT D-BOX
D-BOX creates and redefines realistic, immersive experiences by moving the body and sparking the imagination through effects: motion, vibration and texture. D-BOX has collaborated with some of the best companies in the world to deliver new ways to enhance great stories. Whether it's films, video games, music, relaxation, virtual reality applications, metaverse experience, themed entertainment or professional simulation, D-BOX creates a feeling of presence that makes life resonate like never before. D-BOX Technologies Inc. (TSX: DBO) is headquartered in Montreal with presence in Los Angeles and China. Visit D-BOX.com.
DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS
Certain information included in this press release may constitute 'forward-looking information' within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, activities, objectives, operations, strategy, business outlook, and financial performance and condition of the Company, or the assumptions underlying any of the foregoing. In this document, words such as 'may', 'would', 'could', 'will', 'likely', 'believe', 'expect', 'anticipate', 'intend', 'plan', 'estimate' and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on several assumptions which give rise to the possibility that actual results could differ materially from the Company's expectations expressed in or implied by such forward-looking information and no assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including but not limited to the future plans, activities, objectives, operations, strategy, business outlook and financial performance and condition of the Company.
Forward-looking information is provided in this press release for the purpose of giving information about Management's current expectations and plans and allowing investors and others to get a better understanding of the Company's operating environment. However, readers are cautioned that it may not be appropriate to use such forward-looking information for any other purpose.
Forward-looking information provided in this document is based on information available at the date hereof and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control.
The risks, uncertainties and assumptions that could cause actual results to differ materially from the Company's expectations expressed in or implied by the forward-looking information include, but are not limited to, international trade regulations; concentration of clients; dependence on suppliers; performance of content; exchange rate between the Canadian dollar and the U.S. dollar; ability to implement strategy; consumer preferences and trends; political, social and economic conditions; strategic alliances; credit risk; competition; access to content; technology standardization; future funding requirements; distribution network; indebtedness; global health crises; warranty, recalls and claims; dependence on key personnel and labour relations; legal, regulatory and litigation; intellectual property; security and management of information; and reputational risk through social media. These and other risk factors that could cause actual results to differ materially from expectations expressed in or implied by the forward-looking information are outlined under 'Risk Factors' in the Company's management's discussion and analysis for the period ended March 31, 2025, and discussed in greater detail in the most recently filed Annual Information Form dated June 10, 2025, a copy of which is available on SEDAR+ at www.sedarplus.ca.
Except as may be required by Canadian securities laws, the Company does not intend nor does it undertake any obligation to update or revise any forward-looking information contained in this press release to reflect subsequent information, events, circumstances or otherwise.
The Company cautions readers that the risks described above are not the only ones that could have an impact on it. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial may also have a material adverse effect on the Company's business, financial condition or results of operations.
CONTACT INFORMATION
Josh Chandler Chief Financial OfficerD-BOX Technologies Inc.514-928-8043jchandler@d-box.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Genetic Testing Market Research 2025: Genetic Discoveries Creating New Diagnostic Markets
Discover opportunities and pitfalls in the booming Genetic Testing industry, driven by advances in genetics and lower costs. Explore breakthroughs in Predictive Diagnostics, Pharmacogenomic Testing, and Direct-to-Consumer models across 14 countries and 5 regions. Get insights and forecasts to guide informed investment decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides" has been added to offering. The genetic testing industry is experiencing unprecedented growth, with its potential proving boundless as it expands across various sectors. This growth is being propelled by advancements in our understanding of the genetic basis of health and disease, coupled with decreasing costs. These factors are causing a surge in demand and development within the genetic testing market, presenting both opportunities and challenges. The industry's expansion is significantly influenced by the increasing realization that specific genetic profiles are crucial for the efficacy of novel therapies. Pharmacogenomics is establishing a foothold, underscoring the necessity for genetic testing to tailor drug therapies to individual genetic compositions. As this field grows, it fosters an increasing array of tests, boosting the volume of the traditional genetic testing market and its scope, while also introducing new complexities. The report examines these trends, providing detailed analyses across 14 countries and five regions. It highlights predictive diagnostics, pharmacogenomic testing, and the burgeoning direct-to-consumer segment, offering insights into the technology underpinning the industry. By doing so, it demystifies the complexities, presenting clear information on industry dynamics, opportunities, and challenges. With this comprehensive understanding, stakeholders can anticipate growth patterns and market forecasts over the next five years. The insights provided arm industry experts, investors, and decision-makers with the necessary knowledge to make informed investment decisions and valuations. In a rapidly evolving market, staying informed with the latest data is essential for maintaining a competitive advantage. Key Topics Covered: 1 Market Guides1.1 Genetic Testing - Strategic Situation Analysis & Company Rankings1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Genetic Testing Definition in This Report 2.2 The Genomics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.6 Chromosomes, Genes and Epigenetics 3 Market Overview 3.1 Players in a Dynamic Market3.2 Genetic Tests - Types, Examples and Discussion3.3 Industry Structure 4 Market Trends4.1 Factors Driving Growth 4.1.1 Genetic Discoveries Creating New Diagnostic Markets4.1.2 The Aging Effect4.1.3 Pharmacogenomics Drives Further Growth4.1.4 Oncology and Liquid Biopsy Enter New Era4.1.5 Fertility Practice Growth drives market4.1.6 Direct to Consumer begins to break out 4.2 Factors Limiting Growth4.2.1 Increased Competition Lowers Price 4.2.2 Lower Costs4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside4.3 Instrumentation, Automation and Diagnostic Trends4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point of Care 4.3.3 Instruments Key to Market Share4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing4.3.8 Whole Genome Sequencing, A Brave New World4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Genetic Testing Recent Developments5.1 Recent Developments5.1.1 Importance of This Section 5.1.2 How to Use This Section 5.2 Novitas Rescinds Coverage for Multiple Genetic Tests5.3 PerkinElmer (now Revvity) Becomes Dx Life Science Firm 5.4 New POC Genotyping Tests Based on Electromagnetic Detection 5.5 GenoMe Dx Launching dPCR Cancer Test 5.6 mDetect To Trial Breast Cancer Liquid Biopsy5.7 Genomics England, Aims to Sequence 100K Newborns 5.8 Juno Diagnostics NIPT With At-Home Sample Collection 5.9 Cardio Diagnostics Launches Genetic Cario Risk Test 5.10 Universal Genetic Testing in Breast Cancer Further Supported5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests 5.12 MyOme Lands Investment for WGS5.13 Type 2 Diabetes GWAS Enables Risk Prediction 5.14 LetsGetChecked to Acquire Veritas Genetics 5.15 Guardant Health Plans New Comprehensive Assay 5.16 Tesis Labs Raises $20M 5.17 Sema4: Sema4 Elements 5.18 Clarified Precision Medicine Acquires Interpares Biomedicine5.19 Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA 5.20 Illumina, Belgium Genetic Centers Partner on WGS-Based Dx5.21 NIH, Genomics England Launch Sequencing Studies Using Nanopore Technology5.22 Progenity Revenues Fall on COVID-19 Effect 5.23 Natera Launches Tumor Genomic Profiling Assay5.24 23andMe To Go Public5.25 Guardant Health to Offer Tumor Tissue Sequencing 5.26 Ancestry Quits Health Offering5.27 DTC Firm MyDNA Merges With Gene by Gene 5.28 Aetna Coverage for NIPT to Include All Pregnancies5.29 Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing5.30 Tumor, Germline Testing of Cancer Patients Can Give Discordant Results 6 Profiles of Key Companies6.1 10x Genomics, Inc. 6.2 23andME Inc.6.3 Abbott Laboratories 6.4 Adaptive Biotechnologies 6.5 Admera Health, LLC6.6 Agilent/Dako6.7 Akonni Biosystems6.8 Amoy Diagnostics Co., Ltd. 6.9 LLC6.10 Anchor Dx 6.11 Arc Bio 6.12 Arrayit Corporation 6.13 ARUP Laboratories6.14 Aus Diagnostics6.15 BaseClear 6.16 Baylor Miraca Genetics Laboratories 6.17 Beckman Coulter Diagnostics 6.18 Becton, Dickinson and Company 6.19 BGI Genomics Co. Ltd 6.20 Bioarray Genetics 6.21 Biocept, Inc. 6.22 Biodesix Inc. 6.23 BioFluidica 6.24 BioGenex 6.25 Biolidics Ltd6.26 bioMerieux Diagnostics6.27 Bioneer Corporation6.28 Bio-Rad Laboratories, Inc6.29 Bio-Techne6.30 C2i Genomics 6.31 CareDx 6.32 Caris Molecular Diagnostics6.33 CellMax Life 6.34 Centogene 6.35 Cepheid (Danaher) 6.36 Circulogene 6.37 Clinical Genomics6.38 Color Genomics 6.39 Complete Genomics, Inc. - A BGI Company 6.40 CosmosID 6.41 Dante Labs.6.42 Datar Cancer Genetics Limited 6.43 Diasorin S.p.A. 6.44 Element Biosciences6.45 Element Biosciences6.46 Epic Sciences6.47 Epigenomics AG.6.48 Eurofins Scientific 6.49 Excellerate Bioscience 6.50 Fabric Genomics 6.51 Freenome 6.52 Fujirebio 6.53 Fulgent Genetics 6.54 Gene by Gene, Ltd. 6.55 Genedrive 6.56 GeneFirst Ltd.6.57 Genetron Holdings 6.58 Genomics England 6.59 Genomics Personalized Health (GPH)6.60 GenomOncology 6.61 Genzyme Corporation 6.62 Grifols 6.63 Guardant Health 6.64 Guardiome 6.65 HeiScreen 6.66 Helix 6.67 Helix OpCo6.68 Helomics6.69 Hologic 6.70 HTG Molecular Diagnostics 6.71 Human Longevity, Inc. 6.72 iCellate 6.73 Illumina 6.74 Incell Dx 6.75 Inivata 6.76 Integrated Diagnostics6.77 Invitae Corporation 6.78 Invivoscribe 6.79 Karius 6.80 Letsgetchecked 6.81 Lunglife AI Inc 6.82 Macrogen 6.83 MDNA Life SCIENCES, Inc.6.84 MDx Health 6.85 Medgenome6.86 Menarini Silicon Biosystems 6.87 Meridian Bioscience 6.88 Mesa Biotech (Thermo Fisher) 6.89 Mesa Laboratories, Inc. 6.90 Metabiomics Corp 6.91 miR Scientific 6.92 MNG Labs 6.93 NantHealth, Inc. 6.94 Natera 6.95 Nebula Genomics6.96 NeoGenomics 6.97 New England Biolabs, Inc. 6.98 NGeneBio6.99 Novogene Bioinformatics Technology Co., Ltd.6.100 Omega Bioservices 6.101 Oncocyte6.102 OncoDNA 6.103 OpGen 6.104 ORIG3N, Inc. 6.105 Origene Technologies 6.106 Oxford Nanopore Technologies 6.107 Pacific Biosciences 6.108 Panagene 6.109 PathoQuest S.A. 6.110 Perkin Elmer (now Revvity) 6.111 Personal Genome Diagnostics6.112 Personalis.6.113 Precipio 6.114 PrecisionMed6.115 Promega 6.116 Protagen Diagnostics 6.117 Qiagen 6.118 QuantuMDx 6.119 Roche Molecular Diagnostics 6.120 Roswell Biotechnologies 6.121 Seegene6.122 Sema4 Holdings6.123 6.124 Siemens Healthineers 6.125 simfo GmbH 6.126 Singlera Genomics Inc.6.127 Singular Genomics 6.128 SkylineDx 6.129 Standard BioTools 6.130 Sure Genomics, Inc. 6.131 Sysmex 6.132 Sysmex Inostics6.133 Tempus Labs, Inc. 6.134 Thermo Fisher Scientific Inc. 6.135 Ultima Genomics 6.136 Ultima Genomics 6.137 Variantyx 6.138 Vela Diagnostics 6.139 Volition 6.140 Vyant Bio 6.141 Zymo Research Corp 7 Global Market Size7.1 Global Market by Country7.2 Global Market by Application7.3 Global Market by Technology7.4 Global Market by Product7.5 Global Market by User 8 Market Sizes by Application8.1 Newborn Testing Market8.2 NIPT Market8.3 Predictive Testing Market8.4 Oncology Testing Market8.5 DTC Testing Market8.6 Other Testing Market 9 Global Genetic Testing Market by Technology9.1 PCR Testing Market9.2 NGS Market9.3 Cytogenetic Testing Market9.4 Other Testing Market 10 Global Genetic Testing Market by Product10.1 Instruments Market10.2 Reagents and Kits Market10.3 Software Market10.4 Services Market 11 Global Genetic Testing Market by User11.1 Academic Market11.2 Clinical Market11.3 Pharmaceutical Market11.4 Industrial and Other Market 12 The Future of Genetic Testing 13 Appendices13.1 United States Medicare System: Laboratory Fees Schedule13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Single Cell Genomics Market Research 2025: Immuno-oncology, Research Range, Technology Maturity & Convergence, Declining Costs Bolster Growth
Discover the potential of Single Cell Genomics in our latest report. As it revolutionizes healthcare, identify opportunities, growth expectations, and market potential. Stay ahead with insights into this booming field that is redefining genomics and biotechnology. Ideal for management teams. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Single Cell Genomics Markets: Forecasts by Analyte, Product, Workflow, User, Application and Country with Executive and Consultant Guides" has been added to offering. The market for SCG is experiencing a notable surge as it opens new doors in understanding the genomics of individual cells. This leap forward in biotechnology not only inspires fresh discoveries but also enhances our approach to personalized medicine and precision healthcare. Key stakeholders in the healthcare and biotechnology industries should take note of the opportunities SCG presents, from improving patient outcomes to developing innovative therapeutic strategies. This report is designed to equip management teams with insights into the pivotal developments in SCG, including technological advancements and the accompanying strategic opportunities. As the SCG technology outpaces current market expectations, it's crucial for business leaders to stay informed about the potential opportunities and pitfalls that accompany this rapid evolution. The report sheds light on growth expectations, possible market size, and the interplay between genomics, immunology, and SCG, aiding readers in making informed strategic decisions. Single Cell Genomics (SCG) is revolutionizing the scientific research and development landscape, offering transformative insights across healthcare and biotechnology sectors. This digital press release outlines the findings of a comprehensive new report exploring whether SCG could potentially replace traditional genomics. The implications of SCG are vast, with applications extending from identifying novel life forms to uncovering new diseases and pioneering cures. As the technology continues to evolve, its footprint in clinical applications is expanding, driving substantial market growth. As SCG continues to transition from laboratory research to practical clinical applications, understanding its potential impact on the market becomes increasingly important. This press release invites stakeholders to delve into the report for a thorough analysis of the technological trajectory, market dynamics, and future prospects of SCG. By doing so, they can harness the technology's potential, ensure competitive edge, and contribute to the broader goal of advancing human health. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What is Single Cell Genomics?2.2 SCG - Still Early Days2.3 Market Definition2.4 Methodology2.5 Sizing the Genome - Not What You Think 3 Single Cell Genomics - Guide to Technology3.1 Isolating Single Cells3.1.1 FACS3.1.2 LCM3.1.3 Micromanipulators3.1.4 Microfluidics3.2 Amplification3.2.1 WTA - Whole Transcriptome Amplification3.2.2 WGA - Whole Genome Amplification3.3 PCR3.4 NGS3.5 Microarray3.6 Digital Spatial Profiling (DSP) Technology 4 Industry Overview4.1 Academic Research Lab4.2 Diagnostic Test Developer4.3 Instrumentation Supplier4.4 Chemical/Reagent Supplier4.5 Pathology Supplier4.6 Independent Clinical Laboratory4.7 Public National/regional Laboratory4.8 Hospital Laboratory4.9 Physicians Office Lab (POLS)4.10 Audit Body4.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 Immuno-oncology5.1.2 Research Range5.1.3 Technology Maturity & Convergence5.1.4 Declining Costs5.2 Factors Limiting Growth5.2.1 Competition5.2.2 Instrument Integration5.2.3 Technology Shift5.2.4 Technology Limitations5.3 Technology Development5.3.1 Spatial Profiling5.3.2 Integration5.3.3 Big Data5.3.4 Kits and Commodities5.4 Instrumentation, Automation and Diagnostic Trends5.4.1 Traditional Automation and Centralization5.4.2 The New Automation, Decentralization and Point Of Care5.4.3 Instruments Key to Market Share5.4.4 Bioinformatics Plays a Role5.4.5 PCR Takes Command5.4.6 Next Generation Sequencing Fuels a Revolution5.4.7 NGS Impact on Pricing5.4.8 Whole Genome Sequencing, A Brave New World5.4.9 Companion Diagnostics Blurs Diagnosis and Treatment5.4.10 Shifting Role of Diagnostics 6 Single Cell Genomics Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Scale Biosciences announces ScalePlex to simplify single cell genomics6.3 10x Genomics Launches 5,000-Plex Gene Panel for Xenium6.4 NIH researchers develop AI drug matching tool6.5 Curio Bioscience to Transform Single-Cell Sequencing Data into Spatial Context .. 1536.6 Factorial Biotechnologies Unveils Mosaic6.7 Deepcell and NVIDIA collaborate to advance AI in single cell research6.8 OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies6.9 Beckman Coulter and 10x Genomics partner6.10 MGI and Xpress Genomics to Advance Single-cell RNA-Sequencing6.11 Single-Cell Sequencing Reveals Traits in Cereal Crops6.12 Single-cell Genomics meets Human Genetics6.13 Singular Genomics Launches Kits for Single Cell Sequencing6.14 Scale Biosciences Introduces Disruptive Single-Cell Profiling Solutions6.15 Singleron showcases latest single cell sequencing technology6.16 Oxford Nanopore to Make Single-cell Sequencing Accessible to Any Laboratory . 1686.17 Single-Cell RNA-seq Method Enables Profiling Live Cells6.18 Novogene Launches New Single-Cell Lab6.19 New DNA Atlas Provides Clues for Heart Disease Risk6.20 BioSkryb Genomics Launches ResolveOME6.21 Parse Biosciences Expands Single-Cell Product Line6.22 Massively Multiplexed Single-Cell In Situ Spatial Genomics Now in U.S. Market6.23 Pfizer Centralizes Single Cell Data on Seven Bridges System6.24 Consortium to Standardize Single-Cell Sequencing6.25 Scienion, Cellenion Enter Licensing Deal6.26 Immunai Acquires Swiss Bioinformatics Firm Nebion6.27 Startup MiCareo Targets Rare Cell Isolation Market6.28 Parse Biosciences Lowers Cost Barriers to Single-Cell Transcriptomics6.29 Deepcell Advancing Tech for Single-Cell Genomics6.30 10x Genomics Outlines 2021 Growth Plans6.31 Single-Cell Genomics Firm Analytical Biosciences Inks Deal with BioMap6.32 IsoPlexis Features Cheaper, More Flexible Single-Cell Proteomic Systems6.33 DNTR-Seq Combines WGS, Transcriptomics in Single Cells6.34 BitBiome Builds Single-Cell Bacterial Sequencing Business6.35 S2 Genomics Signs Distribution Agreements for Asia-Pacific6.36 Single-Cell COVID-19 Study Investigates Immune Hyperactivation6.37 Levitas Bio to Launch Magnetic Levitation Cell Separation Platform6.38 Single-Cell and Spatial Genomics6.39 Single-Cell Genomics6.40 Namocell, Takara Bio, HepaTx Partner on Single-Cell Genomics6.41 Vizgen Launches With $14M Series A Financing6.42 SeqWell Raises $9M in Series B Round 7 Profiles of Key Single Cell Genomics Companies7.1 10x Genomics, Inc.7.2 Admera Health, LLC7.3 Agilent7.4 Beckman Coulter Diagnostics (Danaher)7.5 Becton, Dickinson and Company7.6 Berkley Lights7.7 BGI Genomics Co. Ltd7.8 BioGenex7.9 Bio-Rad Laboratories, Inc7.10 BioSkryb Genomics7.11 Bitbiome7.12 Bruker7.13 Cell Microsystems7.14 Cellenion (BICO)7.15 CellSorter7.16 Cytek Biosciences7.17 Cytena7.18 Deepcell7.19 Dolomite Bio (Unchained Labs)7.20 Element Biosciences7.21 Epic Sciences7.22 Fluent Biosciences7.23 Fluxion Biosciences (Cell Microsystems)7.24 Honeycomb Biotechnologies7.25 Illumina7.26 Incell Dx7.27 Leica Biosystems7.28 Menarini Silicon Biosystems7.29 MGI7.30 Miltenyi Biotec7.31 Mission Bio7.32 Myllia Biotechnology7.33 Namocell7.34 NanoCellect Biotechnology7.35 Nanostring7.36 New England Biolabs, Inc.7.37 Novogene7.38 Oxford Nanopore Technologies7.39 Pacific Biosciences7.40 Parse Biosciences7.41 Partek7.42 Qiagen7.43 Revvity7.44 Roche Diagnostics7.45 S2 Genomics7.46 Scale Biosciences7.47 Singleron Biotechnologies7.48 Singular Genomics7.49 Singulomics7.50 Sony Biotechnology7.51 Standard BioTools7.52 Stemcell Technologies7.53 Takara Bio7.54 Thermo Fisher Scientific7.55 Ultima Genomics7.56 Vizgen7.57 Watchmaker Genomics 8 Single Cell Genomics Global Market Size8.1 Global Market Overview by Country8.2 Global Market Size by Analyte - Overview8.3 Global Market by Product - Overview8.4 Global Market by Workflow - Overview8.5 Global Market by End User - Overview8.6 Global Market by Application - Overview 9 Global Market by Analyte9.1 DNA Market9.2 RNA Market9.3 Epigenetic Market9.4 Proteomic Market9.5 Multiomics Market 10 Single Cell Genomics Market by Product10.1 Instrument Market10.2 Reagent Market10.3 Software & Other Market 11 Single Cell Genomics Market by Workflow11.1 Cell Isolation Market11.2 Sample Preparation Market11.3 Genomic Analysis Market 12 Single Cell Genomics Market by End User12.1 Research Market12.2 BioPharma Market12.3 Clinical Market 13 Global Market by Application13.1 Oncology Market13.2 Immunology Market13.3 Microbiology Market13.4 Cell Market13.5 Stem Cell Market13.6 Neurology Market 14 Appendices14.1 FDA Cancer Drug Approvals by Year14.2 Clinical Trials Started Historical14.3 Prevalence of Cancer Treatments For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
New data on mothers who lost jobs during pregnancy show why they fight for change
Arina Kharlamova was cradling her two-month-old daughter when an email popped into her inbox that disrupted the calm of her maternity leave. The message invited the Whitby, Ont., woman to a meeting where she was told she was part of a layoff affecting 30 per cent of the staff at the company she worked for. "It felt like a tailspin, honestly," she recalled. "It was very, very destabilizing, very difficult to be present and continue just focusing on my baby rather than starting to panic." Though she didn't know it at the time, Kharlamova was not alone in her experience. A new study funded by advocacy group Moms at Work and law firm Hudson Sinclair found 15 per cent of 1,390 Canadian moms who gave birth in 2022 and 2023 were dismissed, laid off or had their contracts go unrenewed during their pregnancy, maternity leave or when they returned to work. The respondents were surveyed online and reached through social media posts, email blasts and partner organizations, including women's associations across Canada. The overall Canadian workforce has an average involuntary turnover rate of 5.1 per cent, according to 2023 research from consulting firm Mercer. Allison Venditti, Moms at Work's founder, found the gap striking even though she had long suspected there was a connection between motherhood and job loss. She's heard many stories of pregnant women or new moms losing their jobs. Some, like Kharlamova, were terminated as part of a larger group of layoffs because their employer was closing or downsizing, which means they likely would have lost their jobs regardless. However, Venditti suspects that some companies add pregnant women or mothers to broader layoff lists because they're "out of sight, out of mind" and easy to cut when managers are asked to let go of staff. Others terminate them because they worry parenting will get in the way of work or reduce productivity, she said. When Venditti broached the phenomenon with other people, she says they told her things such as, "it's not a real problem" or "anecdotally hearing it from a couple of women doesn't make it true." Realizing that 'in order to fix the problem, you have to show that it's a problem," she set off to collect data. At 15 per cent, the findings suggests this group has more than three times the involuntary departure rate as the broader working population. That wound up being "validating" for Deborah Hudson, a Toronto employment lawyer whose firm co-funded the survey. She's had at least 100 clients, including three in a recent week, draw a link between their pregnancies and their unemployment. Employers cannot lay off workers because they've taken leave but are allowed to terminate employees during their leave if the reason for the cut is entirely unrelated to them being pregnant or giving birth, Hudson said. That means moms on parental leave can legally be laid off if their employer goes out of business, closes one of its divisions or cuts a wide swath of its workforce to cope with mounting costs. But a company can't hire someone to temporarily cover a leave and then terminate the original worker to give the job to their replacement for the long term, Hudson says, because Canadian laws dictate that employees on parental leave must be reinstated to their original position or a comparable role upon their return. In these cases and others, employers are betting their employees won't go to lawyers, she says. Employers that cut staff as a result of their impending or current parental status are often hoping workers won't have the time, energy or funding to fight them, Venditti said. When they do, she said it often ends up in a settlement because no one wants to endure a lengthy and expensive legal process. "These are women who have been on maternity leave and are often getting 55 per cent (of their wages through employment insurance) who need to go back to work and are, in most instances, not in a financial position to go after their company because they're trying to find daycare and a new job," she said. While the bulk of Canadian mothers Moms at Work surveyed kept their jobs through pregnancy, 16 per cent were denied flexible work during that time and 11 per cent said they were discouraged from attending prenatal appointments. After giving birth but still on leave, 21 per cent said they were pushed to work while off with their baby and 29 per cent reported feeling pressured to return early. When they were back on the job, 26 per cent reported reduced earnings because they were demoted to lower paying jobs or got fewer bonuses and commissions. Twenty-five per cent were denied promotions and one in six were reassigned "undesirable duties." Those numbers suggest to Venditti that 'women are coming back to organizations that are making it very clear that they don't want them there.' "If they're not pushing you out the door, many places are trying," she said. Companies should instead think more long-term, said Beth Wanner, a Regina-based marketing executive who started Mother Cover, a firm supporting workers that take leave. She said about a third of parents leave their jobs within 18 months of returning from parental leave. Many make the leap to new companies because they felt unsupported during or after pregnancy at their last employer but would have stuck around if they were afforded more flexible work hours or weren't overlooked for promotions or raises. With companies spending up to 200 per cent of someone's salary to replace employees gone for good and pouring months into training new workers, she said there's not just a moral case but also a business case for them to treat women better during and after their pregnancies. "This isn't about charity," she said. "This isn't about just doing what's right." It isn't only companies with a role to play. Venditti said there is much the federal government can do as well. Because Canada's current employment insurance program requires recipients to have worked between 420 and 700 hours prior to a leave, when moms lose their jobs during or following pregnancy, they've likely burned through all of or most of their eligibility. She'd like to see income support for mothers not be contingent on hours worked and be more generous than EI, which pays up to 55 per cent of a woman's salary. She envisions those supports could be offered through a program dedicated just for parental leave, rather than the traditional EI system. "EI was designed as a protection but many, many, many people don't qualify for it anymore," she said. "The bottom line is, EI isn't working for most mothers." This report by The Canadian Press was first published June 11, 2025. Tara Deschamps, The Canadian Press